01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Electronic supplementary material
Background
Methods
Patients
DNA extraction and bisulfite modification
Statistical analysis
Results
Demographic and clinicopathological data
No.
|
Average
|
SD
|
P-value
|
|
---|---|---|---|---|
Sex
|
||||
M
|
121
|
75.48
|
7.173
|
0.233
|
F
|
51
|
76.97
|
8.216
|
|
Age
|
||||
<64 years
|
87
|
75.97
|
8.274
|
0.936
|
≥64 years
|
85
|
75.87
|
6.674
|
|
Gross type
|
||||
Mass forming
|
141
|
75.66
|
7.616
|
0.702 (ANOVA)
|
Periductal infiltrative
|
8
|
78.62
|
3.790
|
0.558 (KW)
|
Intraductal growth
|
18
|
76.73
|
7.110
|
|
Mixed
|
5
|
76.16
|
10.837
|
|
Multiplicity
|
||||
single
|
147
|
75.73
|
7.898
|
0.422
|
multiple
|
25
|
77.04
|
4.501
|
|
T stage
|
||||
pT1
|
48
|
78.08
|
6.972
|
0.049 (ANOVA)
|
pT2a
|
38
|
73.08
|
9.417
|
0.012 (KW)
|
pT2b
|
14
|
76.12
|
4.010
|
|
pT3
|
47
|
76.04
|
7.026
|
|
pT4
|
25
|
75.74
|
6.622
|
|
N stage
|
||||
pN0
|
133
|
75.96
|
7.861
|
0.899
|
pN1
|
39
|
75.78
|
6.223
|
|
M stage
|
||||
pM0
|
161
|
76.17
|
7.593
|
0.095
|
pM1
|
11
|
72.26
|
4.972
|
0.035 (MW
a)
|
TNM stage
|
||||
I
|
40
|
77.81
|
7.579
|
0.229
|
II
|
37
|
74.42
|
8.747
|
|
III
|
30
|
76.25
|
7.801
|
|
IV
|
65
|
75.45
|
6.406
|
|
Differentiation
|
||||
Well
|
23
|
79.69
|
4.766
|
0.014
|
Moderate
|
94
|
75.95
|
6.857
|
|
Poorly
|
55
|
74.28
|
8.906
|
|
Neural invasion
|
||||
Absent
|
118
|
75.77
|
8.146
|
0.701
|
Present
|
54
|
76.25
|
5.921
|
|
Lymphatic invasion
|
||||
Absent
|
102
|
76.92
|
7.200
|
0.034
|
Present
|
70
|
74.46
|
7.749
|
|
Vascular invasion
|
||||
Absent
|
95
|
76.44
|
8.141
|
0.396
|
Present
|
77
|
75.27
|
6.631
|
0.047 (MW
a)
|
Chronic liver disease
|
||||
Absent
|
130
|
75.95
|
7.497
|
0.936
|
Present
|
42
|
75.84
|
7.617
|
|
Chronic biliary disease
|
||||
Absent
|
159
|
75.93
|
7.679
|
0.962
|
Present
|
13
|
75.82
|
5.108
|
Relationship between LINE-1 methylation level and clinicopathological features
Relationship between tumoral LINE-1 methylation status and cancer-specific survival of patients with ICC
Parameters
|
Hazard ratio (95% C.I.)
|
P-value
|
|
---|---|---|---|
LINE-1 methylation status
|
0.017
|
||
Q4 (
n = 43)
|
Reference
|
||
Q3 (
n = 43)
|
1.575 (0.561–4.602)
|
0.320
|
|
Q2 (
n = 43)
|
3.369 (1.328–8.551)
|
0.011
|
|
Q1 (
n = 43)
|
3.400 (1.349–8.570)
|
0.009
|
|
LINE-1 methylation status
|
Q3, Q4 (
n = 86)
|
||
Q1, Q2 (
n = 86)
|
2.643 (1.443–4.482)
|
0.002
|
|
pTNM staging
|
0.145
|
||
I (
n = 43)
|
Reference
|
||
II (
n = 38)
|
1.636 (0.739–3.622)
|
0.224
|
|
III (
n = 30)
|
0.543 (0.173–1.709)
|
0.297
|
|
IV (
n = 61)
|
1.602 (0.768–3.342)
|
0.209
|
|
T staging
|
0.044
|
||
pT1 (
n = 48)
|
Reference
|
||
pT2a (
n = 38)
|
1.809 (0.866–3.777)
|
0.114
|
|
pT2b (
n = 14)
|
2.344 (0.929–5.913)
|
0.071
|
|
pT3 (
n = 47)
|
0.941 (0.420–2.107)
|
0.883
|
|
pT4 (
n = 25)
|
0.433 (0.123–1.524)
|
0.192
|
|
N staging
|
pN0 (
n = 133)
|
||
pN1 (
n = 39)
|
2.328 (1.304–4.157)
|
0.004
|
|
M staging
|
pM0 (
n = 161)
|
||
pM1 (
n = 11)
|
1.482 (0.533–4.118)
|
0.451
|
|
Gross type
|
0.076
|
||
Mass forming (
n = 141)
|
Reference
|
||
Periductal infiltrative (
n = 8)
|
0
|
0.964
|
|
Intraductal growth (
n = 18)
|
0.134 (0.018–0.971)
|
0.047
|
|
Mixed (
n = 5)
|
2.672 (0.827–8.638)
|
0.101
|
|
Lymphatic emboli
|
Absent (
n = 102)
|
||
Present (
n = 70)
|
2.519 (1.429–4.438)
|
0.001
|
|
Vascular invasion
|
Absent (
n = 95)
|
||
Present (
n = 77)
|
1.111 (0.634–1.945)
|
0.714
|
|
Perineural invasion
|
Absent (
n = 118)
|
||
Present (
n = 54)
|
0.386 (0.181–0.822)
|
0.014
|
|
Tumor border
|
Expanding (
n = 32)
|
||
Infiltrative (
n = 140)
|
2.133 (0.846–5.375)
|
0.108
|
|
Tumor differentiation
|
0.083
|
||
Well (
n = 23)
|
Reference
|
||
Moderate (
n = 94)
|
9.405 (1.283–68.943)
|
0.027
|
|
Poor (
n = 55)
|
9.671 (1.290–72.518)
|
0.027
|
|
Chemotherapy and/or radiotherapy
|
No (
n = 120)
|
||
Yes (
n = 52)
|
0.979 (0.534–1.792)
|
0.944
|
Hazard ratio (95% C.I.)
|
P-value
|
Hazard ratio (95% C.I.)
|
P-value
|
||
---|---|---|---|---|---|
LINE-1 methylation level
a
|
Q3, Q4 (
n = 86)
|
||||
Q1, Q2 (
n = 86)
|
2.643 (1.443–4.482)
|
0.002
|
2.248 (1.205–4.196)
|
0.011
|
|
N staging
|
pN0 (
n = 133)
|
||||
pN1 (
n = 39)
|
2.211 (1.176–4.157)
|
0.014
|
2.749 (1.491–5.066)
|
0.001
|
|
T staging
|
0.025
|
0.130
|
|||
pT1 (
n = 48)
|
Reference
|
Reference
|
|||
pT2 (
n = 52)
|
1.943 (0.979–3.855)
|
0.058
|
0.555 (0.211–1.458)
|
0.232
|
|
pT3 (
n = 47)
|
0.941 (0.420–2.105)
|
0.882
|
0.363 (0.121–1.091)
|
0.071
|
|
pT4 (
n = 25)
|
0.433 (0.123–1.523)
|
0.192
|
0.216 (0.053–0.889)
|
0.034
|
|
Gross type
|
0.076
|
0.064
|
|||
Mass forming (
n = 141)
|
Reference
|
Reference
|
|||
Periductal infiltrative (
n = 8)
|
0
|
0.964
|
0
|
0.972
|
|
Intraductal growth (
n = 18)
|
0.134 (0.018–0.971)
|
0.047
|
0.123 (0.017–0.910)
|
0.040
|
|
Mixed (
n = 5)
|
2.672 (0.827–8.638)
|
0.101
|
2.878 (0.854–9.694)
|
0.088
|
|
Lymphatic emboli
|
Absent (
n = 102)
|
||||
Present (
n = 70)
|
2.519 (1.429–4.438)
|
0.001
|
2.720 (1.168–6.337)
|
0.020
|
|
Perineural invasion
|
Absent (
n = 118)
|
||||
Present (
n = 54)
|
0.386 (0.181–0.822)
|
0.014
|
0.373 (0.162–0.860)
|
0.021
|
|
Differentiation
|
0.083
|
0.638
|
|||
Well (
n = 23)
|
Reference
|
||||
Moderate (
n = 94)
|
9.405 (1.283–68.943)
|
0.027
|
|||
Poor (
n = 55)
|
9.671 (1.290–72.518)
|
0.027
|
Discussion
Parameters
|
Hazard ratio (95% C.I.)
|
P-value
|
|
---|---|---|---|
LINE-1 methylation /lymphatic emboli status
|
0.001
|
||
High/absent (
n = 58)
|
Reference
|
||
Low/present (
n = 28)
|
3.128 (1.523–6.424)
|
0.002
|
|
Low/absent (
n = 44)
|
1.113 (0.460–2.695)
|
0.812
|
|
High/present (
n = 42)
|
0.761 (0.237–2.443)
|
0.647
|
|
Gross type
|
0.073
|
||
Mass forming (
n = 141)
|
Reference
|
||
Periductal infiltrative (
n = 8)
|
0
|
0.972
|
|
Intraductal growth (
n = 18)
|
0.141 (0.019–1.032)
|
0.054
|
|
Mixed (
n = 5)
|
3.013 (0.885–10.254)
|
0.078
|
|
T staging
|
0.152
|
||
pT1 (
n = 48)
|
Reference
|
||
pT2 (
n = 52)
|
0.579 (0. 220–1.526)
|
0.270
|
|
pT3 (
n = 47)
|
0.371 (0.124–1.114)
|
0.077
|
|
pT4 (
n = 25)
|
0.233 (0.056–0.971)
|
0.046
|
|
N staging
|
pN0 (
n = 133)
|
||
pN1 (
n = 39)
|
2.456 (1.341–4.497)
|
0.004
|
|
Perineural invasion
|
Absent (
n = 118)
|
||
Present (
n = 54)
|
0.321 (0.147–0.699)
|
0.004
|
|
Differentiation
|
0.577
|
||
Well (
n = 23)
|
Reference
|
||
Moderate (
n = 94)
|
3.495 (0.332–36.809)
|
0.298
|
|
Poor (
n = 55)
|
3.493 (0.328–37.217)
|
0.300
|